CN106075446A - 一种缓释妇科凝胶及其制备方法 - Google Patents
一种缓释妇科凝胶及其制备方法 Download PDFInfo
- Publication number
- CN106075446A CN106075446A CN201610467232.7A CN201610467232A CN106075446A CN 106075446 A CN106075446 A CN 106075446A CN 201610467232 A CN201610467232 A CN 201610467232A CN 106075446 A CN106075446 A CN 106075446A
- Authority
- CN
- China
- Prior art keywords
- slow release
- gel
- extract
- gynecological gel
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 238000001879 gelation Methods 0.000 title description 2
- 239000002904 solvent Substances 0.000 claims abstract description 20
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 239000003002 pH adjusting agent Substances 0.000 claims abstract description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- -1 card ripple Nurse Chemical compound 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 238000007599 discharging Methods 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- RWLALWYNXFYRGW-UHFFFAOYSA-N 2-Ethyl-1,3-hexanediol Chemical compound CCCC(O)C(CC)CO RWLALWYNXFYRGW-UHFFFAOYSA-N 0.000 claims description 4
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010418 carrageenan Nutrition 0.000 claims description 4
- 239000000679 carrageenan Substances 0.000 claims description 4
- 229920001525 carrageenan Polymers 0.000 claims description 4
- 229940113118 carrageenan Drugs 0.000 claims description 4
- 229960005082 etohexadiol Drugs 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 229950005134 polycarbophil Drugs 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 4
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 claims description 3
- 229960001915 hexamidine Drugs 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 229960004125 ketoconazole Drugs 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 claims description 2
- UUIVKBHZENILKB-UHFFFAOYSA-N 2,2-dibromo-2-cyanoacetamide Chemical compound NC(=O)C(Br)(Br)C#N UUIVKBHZENILKB-UHFFFAOYSA-N 0.000 claims description 2
- KUXUALPOSMRJSW-IFWQJVLJSA-N 2-[6-[[amino-[[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 KUXUALPOSMRJSW-IFWQJVLJSA-N 0.000 claims description 2
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 claims description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 241000193755 Bacillus cereus Species 0.000 claims description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 229920001090 Polyaminopropyl biguanide Polymers 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 229960000583 acetic acid Drugs 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- DMSMPAJRVJJAGA-UHFFFAOYSA-N benzo[d]isothiazol-3-one Chemical compound C1=CC=C2C(=O)NSC2=C1 DMSMPAJRVJJAGA-UHFFFAOYSA-N 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229960002788 cetrimonium chloride Drugs 0.000 claims description 2
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims description 2
- 238000005660 chlorination reaction Methods 0.000 claims description 2
- 229960003993 chlorphenesin Drugs 0.000 claims description 2
- INSRQEMEVAMETL-UHFFFAOYSA-N decane-1,1-diol Chemical compound CCCCCCCCCC(O)O INSRQEMEVAMETL-UHFFFAOYSA-N 0.000 claims description 2
- IPGANOYOHAODGA-UHFFFAOYSA-N dilithium;dimagnesium;dioxido(oxo)silane Chemical compound [Li+].[Li+].[Mg+2].[Mg+2].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O IPGANOYOHAODGA-UHFFFAOYSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- KRPAJLYSLFNDOA-UHFFFAOYSA-N mephenesin carbamate Chemical compound CC1=CC=CC=C1OCC(O)COC(N)=O KRPAJLYSLFNDOA-UHFFFAOYSA-N 0.000 claims description 2
- 229950006838 mephenesin carbamate Drugs 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 claims description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229940087419 nonoxynol-9 Drugs 0.000 claims description 2
- 229920004918 nonoxynol-9 Polymers 0.000 claims description 2
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 229940093424 polyaminopropyl biguanide Drugs 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 239000000186 progesterone Substances 0.000 claims description 2
- 229960003387 progesterone Drugs 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000001540 sodium lactate Substances 0.000 claims description 2
- 235000011088 sodium lactate Nutrition 0.000 claims description 2
- 229940005581 sodium lactate Drugs 0.000 claims description 2
- 235000020712 soy bean extract Nutrition 0.000 claims description 2
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims 1
- 150000001409 amidines Chemical class 0.000 claims 1
- 235000013675 iodine Nutrition 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 239000004302 potassium sorbate Substances 0.000 claims 1
- 235000010241 potassium sorbate Nutrition 0.000 claims 1
- 229940069338 potassium sorbate Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 6
- 210000001215 vagina Anatomy 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 3
- 229940071110 amino-cerv Drugs 0.000 abstract description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229960000502 poloxamer Drugs 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于医药技术领域,涉及一种妇科用药及其制备方法。一种缓释妇科凝胶,包括如下质量百分数的原料:凝胶剂0.1‑20%、缓释剂0.1‑20%、增溶剂0.1‑20%、活性成分0.001‑20%、pH调节剂0.01‑20%、溶剂20‑99.5%。本发明的缓释妇科凝胶,能够延长药物在引道局部的作用时间,并且使阴道pH保持3‑8,大大提高了活性成分的治疗效果。
Description
技术领域
本发明属于医药技术领域,涉及一种妇科用药及其制备方法。
背景技术
正常生育年龄的妇女,体内存在足量的雌激素,和阴道里占主导地位的乳酸杆菌一起,使阴道处于一种酸性的环境(PH值大约3.8-4.4)。正常情况下,阴道上皮细胞随月经周期中雌、孕激素的作用,发生周期性变化,特别是表层细胞,细胞内富含糖原,糖原分泌后,经寄生于阴道内的阴道杆菌的作用将其分解为乳酸,使阴道内保持PH为4.5的酸性环境,从而抑制致病菌的繁殖。故维持阴道的正常pH有利于阴道的自净或灭菌作用。当生殖道有炎症或PH值上升时,阴道内环境发生改变,出现大量杂菌和白细胞。
理想的阴道给药系统(Vaginaldrugdeliverysystem)可用于局部作用药物, 延长作用时间、提高治疗效果, 实现“一剂即愈” (One-dose-to-cure)。也可用于全身作用药物, 避开肝脏首过代谢、提高吸收程度。而传统的阴道用片剂、栓剂、凝胶剂、洗剂等, 存在停留时间短、药物泄漏等不足, 不能实现药物的有效递送,治疗效果欠佳。
发明内容
本发明的目的是提供一种缓释妇科凝胶,通过缓释剂的配伍与使用,达到了活性成分与pH的双效缓释作用,延长凝胶作用时间,改善治疗效果。
为了实现上述目的,本发明采用的技术方案是:一种缓释妇科凝胶,包括如下质量百分数的原料:凝胶剂0.1-20%、缓释剂0.1-20%、增溶剂0.1-20%、活性成分0.001-20%、pH调节剂0.01-20%、溶剂20-99.5%。
所述的凝胶剂选自卡拉胶、卡波姆、羧甲基纤维素钠、羟乙基纤维素、黄原胶、果胶、硅酸镁铝、硅酸镁锂钠、瓜尔豆胶、魔芋胶、海藻酸钠中的一种,或两种以上物质的混合物。
所述的缓释剂选自聚卡波非、泊洛沙姆、透明质酸半胱氨酸乙酯结合物中的一种。
增溶剂选自甘油、丙二醇、丁二醇、戊二醇、辛二醇、吐温、氢化蓖麻油中的一种,或两种以上物质的混合物。
活性成分选自芽孢杆菌提取物、大豆发酵提取物、己二醇、辛甘醇、癸二醇、乙基己基甘油、甲基异噻唑啉酮、聚氨丙基双胍、苯并异噻唑啉酮、氯苯甘醚、苯氧乙醇、脱氧乙酸、对羟基苯甲酸甲酯、对羟基苯甲酸乙酯、孕酮、酮康唑、壬苯醇醚-9、对羟基苯甲酸丙酯、对羟基苯甲酸丁酯、苯扎氯铵、苯甲醇、己脒定二盐、西曲氯铵、氯化铵盐、苯甲酸钠、山梨酸钾、碘丙炔醇乙基氨甲酸酯、布伦波尔、二溴氰基乙酰胺、氯己定二葡糖酸盐、己脒定二盐、土茯苓提取物、地肤子提取物、花椒提取物、蛇床子提取物、枣提取物、苦参提取物中的一种,或两种以上物质的混合物。
pH调节剂选自柠檬酸、柠檬酸钠、乳酸、乳酸钠、磷酸二氢盐、磷酸氢二盐、Tris、三乙醇胺中的一种,或两种以上物质的混合物。
所述的溶剂为去离子水或纯化水
一种缓释妇科凝胶的制备方法,包括如下步骤:
(1) 按比例称取各原料;
(2) 将增溶剂、缓释剂加入到溶剂中,搅拌均匀,再加入凝胶剂,在15-70摄氏度条件下搅拌均匀;
(3) 降温至4-60℃,加入活性成分并缓慢搅拌0.5-2小时,而后使用pH调节剂调节pH至3-8;
(4) 停止搅拌,出料;灌装。
本发明的缓释妇科凝胶,能够延长药物在引道局部的作用时间,并且使阴道pH保持3-8,大大提高了活性成分的治疗效果。
具体实施方式
实例1 本实施例的缓释妇科凝胶,包含以下重量百分比的原料组分:羧甲基纤维素钠1.5%、泊洛沙姆0.5%、甘油3.0%、氯己定二葡糖酸盐0.5%、磷酸二氢钾0.75%、磷酸氢二钾0.02、纯化水93.73%。
本实施例的缓释妇科凝胶,按照以下步骤制备而成:
(1)按上述比例称取各原料;
(2) 将增溶剂甘油、缓释剂泊洛沙姆加入到溶剂纯化水中,搅拌均匀,再加入凝胶剂羧甲基纤维素钠,在50℃条件下搅拌均匀;
(3)降温至25℃,加入活性成分氯己定二葡糖酸盐并缓慢搅拌1 小时,而后加入pH调节剂磷酸二氢钾与磷酸氢二钾,调节pH至4.5;
(4) 停止搅拌,出料;灌装。
实施例2本实施例的缓释妇科凝胶,包含以下重量百分比的原料组分:卡拉胶1.0%、卡波姆1.0%、聚卡波非0.5%、丙二醇1.5%、丁二醇1.0%、甘油2.0%、蛇床子提取物0.5%、柠檬酸1.0%、柠檬酸钠0.5%、去离子水91%。
本实施例的缓释妇科凝胶,按照以下步骤制备而成:
(1)按上述比例称取各原料;
(2)将增溶剂甘油、丙二醇、丁二醇,缓释剂聚卡波非加入到溶剂去离子水中,搅拌均匀,再加入凝胶剂卡拉胶、卡波姆,在55℃条件下搅拌均匀;
(3)降温至20℃,加入活性成分蛇床子提取物并缓慢搅拌1.2小时,而后加入pH调节剂柠檬酸与柠檬酸钠,调节pH至4.5;
(4)停止搅拌,出料;灌装。
实施例3本实施例的缓释妇科凝胶,包含以下重量百分比的原料组分:羟乙基纤维素1.0%、海藻酸钠1.5%、透明质酸半胱氨酸乙酯结合物1.5%、戊二醇2.5%、辛二醇1.0%、酮康唑0.8%、三乙醇胺0.5%、去离子水91.2%。
本实施例的缓释妇科凝胶,按照以下步骤制备而成:
(1)按上述比例称取各原料;
(2)将增溶剂戊二醇、辛二醇,缓释剂透明质酸半胱氨酸乙酯结合物加入到溶剂去离子水中,搅拌均匀,再加入凝胶剂羟乙基纤维素、海藻酸钠,在52℃条件下搅拌均匀;
(3)降温至28℃,加入活性成分酮康唑并缓慢搅拌2小时,而后加入pH调节剂三乙醇胺,调节pH至4.5;
(4)停止搅拌,出料;灌装。
Claims (8)
1.一种缓释妇科凝胶,其特征在于:包括如下质量百分数的原料:凝胶剂0.1-20%、缓释剂0.1-20%、增溶剂0.1-20%、活性成分0.001-20%、pH调节剂0.01-20%、溶剂20-99.5%。
2.根据权利要求1所述的缓释妇科凝胶,其特征在于:所述的凝胶剂选自卡拉胶、卡波姆、羧甲基纤维素钠、羟乙基纤维素、黄原胶、果胶、硅酸镁铝、硅酸镁锂钠、瓜尔豆胶、魔芋胶、海藻酸钠中的一种,或两种以上物质的混合物。
3.根据权利要求1所述的缓释妇科凝胶,其特征在于:所述的缓释剂选自聚卡波非、泊洛沙姆、透明质酸半胱氨酸乙酯结合物中的一种。
4.根据权利要求1所述的缓释妇科凝胶,其特征在于:增溶剂选自甘油、丙二醇、丁二醇、戊二醇、辛二醇、吐温、氢化蓖麻油中的一种,或两种以上物质的混合物。
5.根据权利要求1所述的缓释妇科凝胶,其特征在于:活性成分选自芽孢杆菌提取物、大豆发酵提取物、己二醇、辛甘醇、癸二醇、乙基己基甘油、甲基异噻唑啉酮、聚氨丙基双胍、苯并异噻唑啉酮、氯苯甘醚、苯氧乙醇、脱氧乙酸、对羟基苯甲酸甲酯、对羟基苯甲酸乙酯、孕酮、酮康唑、壬苯醇醚-9、对羟基苯甲酸丙酯、对羟基苯甲酸丁酯、苯扎氯铵、苯甲醇、己脒定二盐、西曲氯铵、氯化铵盐、苯甲酸钠、山梨酸钾、碘丙炔醇乙基氨甲酸酯、布伦波尔、二溴氰基乙酰胺、氯己定二葡糖酸盐、己脒定二盐、土茯苓提取物、地肤子提取物、花椒提取物、蛇床子提取物、枣提取物、苦参提取物中的一种,或两种以上物质的混合物。
6.根据权利要求1所述的缓释妇科凝胶,其特征在于:pH调节剂选自柠檬酸、柠檬酸钠、乳酸、乳酸钠、磷酸二氢盐、磷酸氢二盐、Tris、三乙醇胺中的一种,或两种以上物质的混合物。
7.根据权利要求1所述的缓释妇科凝胶,其特征在于:所述的溶剂为去离子水或纯化水。
8.一种缓释妇科凝胶的制备方法,包括如下步骤:
(1) 按比例称取各原料;
(2) 将增溶剂、缓释剂加入到溶剂中,搅拌均匀,再加入凝胶剂,在15-70 摄氏度条件下搅拌均匀;
(3) 降温至4-60℃,加入活性成分并缓慢搅拌0.5-2 小时,而后使用pH调节剂调节pH至3-8;
(4) 停止搅拌,出料;灌装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610467232.7A CN106075446A (zh) | 2016-06-24 | 2016-06-24 | 一种缓释妇科凝胶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610467232.7A CN106075446A (zh) | 2016-06-24 | 2016-06-24 | 一种缓释妇科凝胶及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106075446A true CN106075446A (zh) | 2016-11-09 |
Family
ID=57253223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610467232.7A Pending CN106075446A (zh) | 2016-06-24 | 2016-06-24 | 一种缓释妇科凝胶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106075446A (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106722750A (zh) * | 2017-01-22 | 2017-05-31 | 天津商业大学 | 用于固化调味酱的凝胶剂 |
CN107412337A (zh) * | 2017-06-21 | 2017-12-01 | 杭州惠博士健康产业有限公司 | 一种透明质酸杀菌避孕凝胶及制作方法 |
CN109908075A (zh) * | 2019-03-19 | 2019-06-21 | 中山大学 | 一种盐酸小檗碱缓释凝胶剂及其制备方法 |
CN110151684A (zh) * | 2019-07-01 | 2019-08-23 | 广州润虹医药科技股份有限公司 | 一种抗菌妇科凝胶及其制备方法和应用 |
CN110575431A (zh) * | 2019-08-28 | 2019-12-17 | 南京天朗制药有限公司 | 一种阴道酸碱缓冲凝胶及制备方法 |
CN110840827A (zh) * | 2019-12-09 | 2020-02-28 | 北京幸福益生再生医学科技有限公司 | 一种妇科抗菌修复凝胶及其制备方法 |
CN112245495A (zh) * | 2020-11-21 | 2021-01-22 | 陕西远志医药生物工程有限公司 | 一种缓释抑菌凝胶及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101683316A (zh) * | 2008-09-26 | 2010-03-31 | 复旦大学 | 一种温度敏感的生物粘附性阴道用原位凝胶缓释制剂 |
CN101744833A (zh) * | 2008-12-02 | 2010-06-23 | 济南宏瑞创博医药科技开发有限公司 | 一种治疗细菌性阴道炎的药物组合物 |
US20110123624A1 (en) * | 2009-11-25 | 2011-05-26 | Michael Zasloff | Formulations comprising aminosterols |
CN102525884A (zh) * | 2010-12-19 | 2012-07-04 | 复旦大学 | 一种用于阴道给药的温敏原位凝胶制剂 |
CN103724455A (zh) * | 2013-12-11 | 2014-04-16 | 四川大学 | 一种透明质酸衍生物及其水凝胶的制备方法 |
CN104188894A (zh) * | 2014-08-11 | 2014-12-10 | 吉林大学 | 布替萘芬温敏凝胶制剂及其制备方法 |
-
2016
- 2016-06-24 CN CN201610467232.7A patent/CN106075446A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101683316A (zh) * | 2008-09-26 | 2010-03-31 | 复旦大学 | 一种温度敏感的生物粘附性阴道用原位凝胶缓释制剂 |
CN101744833A (zh) * | 2008-12-02 | 2010-06-23 | 济南宏瑞创博医药科技开发有限公司 | 一种治疗细菌性阴道炎的药物组合物 |
US20110123624A1 (en) * | 2009-11-25 | 2011-05-26 | Michael Zasloff | Formulations comprising aminosterols |
CN102525884A (zh) * | 2010-12-19 | 2012-07-04 | 复旦大学 | 一种用于阴道给药的温敏原位凝胶制剂 |
CN103724455A (zh) * | 2013-12-11 | 2014-04-16 | 四川大学 | 一种透明质酸衍生物及其水凝胶的制备方法 |
CN104188894A (zh) * | 2014-08-11 | 2014-12-10 | 吉林大学 | 布替萘芬温敏凝胶制剂及其制备方法 |
Non-Patent Citations (6)
Title |
---|
于秀路等主编: "《新编外用药物手册》", 30 September 1996 * |
梅兴国主编: "《生物技术药物制剂基础与应用》", 31 October 2004 * |
浙江省地质科学研究所编: "《粘土和粘土矿物译文选辑》", 31 December 1981 * |
程刚主编: "《生物药剂学》", 31 August 2015 * |
郝利平主编: "《食品添加剂》", 30 June 2004 * |
韦超等主编: "《药剂学》", 31 August 2012 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106722750A (zh) * | 2017-01-22 | 2017-05-31 | 天津商业大学 | 用于固化调味酱的凝胶剂 |
CN107412337A (zh) * | 2017-06-21 | 2017-12-01 | 杭州惠博士健康产业有限公司 | 一种透明质酸杀菌避孕凝胶及制作方法 |
CN109908075A (zh) * | 2019-03-19 | 2019-06-21 | 中山大学 | 一种盐酸小檗碱缓释凝胶剂及其制备方法 |
CN109908075B (zh) * | 2019-03-19 | 2022-03-29 | 中山大学 | 一种盐酸小檗碱缓释凝胶剂及其制备方法 |
CN110151684A (zh) * | 2019-07-01 | 2019-08-23 | 广州润虹医药科技股份有限公司 | 一种抗菌妇科凝胶及其制备方法和应用 |
CN110575431A (zh) * | 2019-08-28 | 2019-12-17 | 南京天朗制药有限公司 | 一种阴道酸碱缓冲凝胶及制备方法 |
WO2021036294A1 (zh) * | 2019-08-28 | 2021-03-04 | 南京天朗制药有限公司 | 一种阴道酸碱缓冲凝胶及制备方法 |
CN110575431B (zh) * | 2019-08-28 | 2021-08-03 | 南京天朗制药有限公司 | 一种阴道酸碱缓冲凝胶及制备方法 |
CN110840827A (zh) * | 2019-12-09 | 2020-02-28 | 北京幸福益生再生医学科技有限公司 | 一种妇科抗菌修复凝胶及其制备方法 |
CN112245495A (zh) * | 2020-11-21 | 2021-01-22 | 陕西远志医药生物工程有限公司 | 一种缓释抑菌凝胶及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106075446A (zh) | 一种缓释妇科凝胶及其制备方法 | |
CN101288643B (zh) | 含有他克莫司的凝胶剂组合物及其制备方法和药物应用 | |
Fasola et al. | Labia majora augmentation with hyaluronic acid filler: technique and results | |
CN108635585A (zh) | 一种治疗老年性阴道炎的药物组合物及温敏缓释凝胶剂和制备方法 | |
CN101889974A (zh) | 一种壳聚糖避孕凝胶及其制备方法 | |
CN103705922A (zh) | 以糖皮质激素为活性成分的外用药物组合物 | |
CN101926755B (zh) | 穿琥宁原位凝胶制剂及其制备方法 | |
CN111012737A (zh) | 氟比洛芬钠凝胶及其制备方法 | |
US20180104346A1 (en) | Vaginal Bioadhesive Boric Acid Formulation and Its Preparation Method | |
CN106176484A (zh) | 凝润调理乳及其制备方法 | |
CN103251550B (zh) | 含有秋水仙碱的透皮给药膏剂及其制备方法 | |
CN104784223A (zh) | 一种具有止痒功能的组合物及其制备方法 | |
CN101224186A (zh) | 双氯芬酸依泊胺凝胶剂、其制备方法及药物用途 | |
CN101933895A (zh) | 硝酸芬替康唑的阴道栓剂组合物 | |
CN102526005A (zh) | 甲磺酸去铁胺在制备治疗绝经后骨质疏松疾病药物中的用途 | |
CN105362289B (zh) | 一种阴道滞留硼酸制剂及其制备方法 | |
CN103169764B (zh) | 一种治疗湿疹的药物组合物及其制备方法 | |
JP2007077150A (ja) | 酸−酸緩衝系を含有する無水組成物 | |
CN103908425A (zh) | 一种抗真菌用氟曲马唑软膏制剂及其制备工艺 | |
CN104000814B (zh) | 一种防治痛风性关节炎的药物组合物及其用途 | |
CN102949725B (zh) | 一种含有糖皮质激素和nos抑制剂的注射药物组合物 | |
CN106038723A (zh) | 一种治疗骨性膝关节炎的中药凝胶膏及其制备方法 | |
CN103142619B (zh) | 一种治疗皮炎的药物组合物及其制备方法 | |
CN106266037B (zh) | 一种液体凝胶及其制备方法 | |
CN107184619A (zh) | 一种妇科抗菌修复凝胶配方及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161109 |
|
RJ01 | Rejection of invention patent application after publication |